Abcentra

We are a clinical-stage biopharmaceutical company focused on bringing new and better treatment options to patients with coronary artery disease (CAD), with the aim of preventing heart attacks. Abcentra’s core technology allows for targeting of oxidized low-density lipoprotein (OxLDL), a novel and highly specific approach to quelling coronary inflammation, which has the potential to maximize efficacy and safety compared to other anti-inflammatory therapies for CAD. The Company’s clinical-stage product, Orticumab, is a first-in-class monoclonal antibody against oxidized LDL (OxLDL), the critical driver of atherosclerotic disease and heart attack. Abcentra is developing Orticumab for secondary prevention of cardiac events after an acute coronary syndrome (ACS), with further plans to expand use of orticumab into primary prevention in CAD patients with coronary inflammation.